CritiTech
Pharmaceutical particle engineering for advanced drug delivery.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
$7.5m | Early VC | ||
| Total Funding | 000k | ||
Related Content
Founded in 2001 by Bala Subramaniam, CritiTech is a Contract Development and Manufacturing Organization (CDMO) that specializes in enhancing drug formulations. The company is headquartered in Lawrence, Kansas, and moved into a new 10,000-square-foot facility in 2013 to house its administration, R&D, laboratories, and manufacturing operations under one roof. The leadership team includes experienced pharmaceutical executives such as Chairman Sam Campbell, President Matthew McClorey, and CEO David Johnston.
CritiTech operates on a fee-for-service basis, partnering with pharmaceutical companies to solve complex formulation challenges, particularly for poorly water-soluble drugs. The company serves a range of clients, including some of the top 15 largest pharmaceutical firms, to advance drugs from proof-of-concept through to Phase III cGMP clinical production. The business model is centered on providing specialized particle engineering services and analytical support throughout the drug development lifecycle.
The company's core services are centered around two key technologies: Spray Drying and a proprietary Supercritical Precipitation (SCP) platform called Purcision™. These technologies are used to engineer drug particles with optimized size, shape, and surface area, which can improve a drug's solubility, bioavailability, and overall efficacy. The award-nominated Purcision™ platform uses supercritical carbon dioxide as an anti-solvent to create fine, uniform particles, enabling the development of highly potent or targeted drug formulations, including those for inhalation. CritiTech can handle a wide variety of compounds, including potent, cytotoxic, and non-potent APIs, and is licensed to manage Schedule II-V controlled substances.
Keywords: Contract Development Manufacturing Organization, CDMO, particle engineering, drug formulation, spray drying, supercritical precipitation, bioavailability enhancement, pharmaceutical development, active pharmaceutical ingredient, cGMP manufacturing, analytical services, drug delivery, poorly soluble drugs, clinical trial materials, supercritical fluid technology, Purcision, formulation challenges, potent compounds, cytotoxic drugs, inhaled drug delivery